Fermenta Biotech Ltd
Add to watch list to get report alerts
BSE Code:
506414
NSE Code:
Business Profile
Business Profile
DIL (DIL), formerly known as Duphar-Interfran, through joint ventures and subsidiaries makes bulk drugs and provides contract research and custom synthesis services for pharmaceutical multinationals for drug discovery and development. Incorporated on May 1, 1951, it became a public limited company with effect from Apr. 9, 1963 and got its current name in 1971.
The company specializes in synthesis of fine organic compounds, chiral building blocks and intermediates. Expertise includes developing small size, aromatic and non-aromatic, functionalized heterocycles; enzyme-mediated asymmetric synthesis of hydroxyesters; protection of amino acids at amino and carboxyl functionalities; and synthesis of compounds having peptide linkage.
Qualified synthetic chemists develop and produce tailor-made compounds (gms to multi-kgs) for the pharmaceutical and biotechnology industries. Services cover both individual projects, as well as working exclusively as permanent team members for clients. The company has modern facilities for organic synthesis and industrial biotechnology in Thane, Maharashtra. The company has shifted bulk manufacturing business to Kullu which is a tax free zone.
The company has a new R&D centre and rented out of excess space available at its premises at Thane and Worli for generating consistent lease rentals. It has started providing research services (through FTE & custom synthesis models) to a few of the leading MNC clients. Research Support International (subsidiary) and Evotec have formed a joint venture, Evotec-RSIL, for the design, synthesis and management of compound libraries. The company is to amalgamate its 100% subsidiary, White Stripes Entertainment, with itself. The company has built successful partnerships with over 50 multinational pharma companies.
The registered office is at DIL Complex, Majiwada, Ghodbunder Road, Thane-400610.
Financials
DIL registered a 142.19% growth in net profit to Rs 8.84 million for the quarter ended June 2007 from a profit of Rs 3.65 million for the quarter ended June 2006.
Net sales for the quarter declined 2.12% to Rs 18.51 million for the quarter ended June 2007 from Rs 18.91 million for the quarter ended June 2006.
Total income rose 20.36% to Rs 24.47 million for the quarter ended June 2007 from Rs 20.33 million for the quarter ended June 2006.
The earnings per share (EPS) of the company stood at Rs 3.85 in the quarter ended June 2007.
On consolidated basis, DIL registered a profit of Rs 15.99 million for the quarter ended June 2007.
It recorded a net sales of Rs 110.7 million for the quarter.
Total income was Rs 117.63 million for the quarter ended June 2007.
The earnings per share of the company stood at Rs 6.91 for the quarter ended June 2007.
Recent Developments
09-JUL-07
DIL has announced the formation of a joint venture Evotec-RSIL between its subsidiary Research Support International and Evotec for the design, synthesis and management of compound libraries.
21-FEB-07
On February 21, 2007, the board of directors approved the amalgamation of its 100% subsidiary White Stripes Entertainment with the company.